Product Name:
ALK-AKCD
Product Number:
ab-nk003-2
Target Full Name: Anaplastic lymphoma receptor-tyrosine kinase
Target Alias: Anaplastic lymphoma kinase; Anaplastic lymphoma kinase (Ki-1); Anaplastic lymphoma receptor tyrosine kinase; CD246; Kinase ALK; TFG/ALK; ENSG00000171094
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK003-2
Antibody Target Type: Pan-specific
Protein UniProt: Q9UM73
Protein SigNET: Q9UM73
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ALK sequence peptide Cat. No.: PE-01BBZ90
Antibody Immunogen Sequence: LLVSQQAKREEERSPAAC
Antibody Immunogen Description: Corresponds to amino acid residues L1424 to A1440; After catalytic domain
Production Method: Corresponds to amino acid residues L1424 to A1440; After catalytic domain
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 140-170 kDa.
Related Product 1: ALK-AKCD blocking peptide
Related Product 2: ALK-BKCD pan-specific antibody (Cat. No.: AB-NK003-3)
Related Product 3: ALK-pY1092 phosphosite-specific antibody (Cat. No.: AB-PK518)
Related Product 4: ALK-pY1096 phosphosite-specific antibody (Cat. No.: AB-PK519)
Related Product 5: ALK-pY1507 phosphosite-specific antibody (Cat. No.: AB-PK520)
Scientific Background: ALK is a protein-tyrosine kinase of the TK group and ALK family. It is a neuronal receptor for the ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor. ALK signals via MyD88 and is important in neuronal differentiation and development. Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Chromosomal rearrangments (most common), mutations, and amplifications with the ALK gene are associated with numerous tumours including: anaplastic large cell lymphomas, neuroblastomas, and non-small cell lung cancer. These fusion proteins, as well as other mutations and amplifications, likely confer heightened (possibly consititutive) phosphotransferase activity and promote cell growth and anti-apoptotic pathways such as the Akt and MAPK pathways. In Neuroblastoma 3 (NBLST3), there was constitutive activation, and Endoplasmic Reticulum or Golgi Apparatus localization when ALK had gain of function mutations with F1174I or F1174V (located in the kinase catalytic subdomain III) or R1275Q (located just before the kinase catalytic Subdomain VII). Translocations of the ALK gene resulting in fusion proteins with NPM1 are observed in 5-10% of non-Hodgkin lymphomas, with CARS and SEC31A in inflammatory myofibroblastic tumours (IMTs) and ALO17 in anaplastic large-cell lymphoma (ALCL). The genes C/EBPB, and BCL2A1 are essential for ALCL growth and transcriptionally induced by ALK.